Understanding

Atopic Dermatitis (AD)

Disease Activity...

Exploring WHAT CAN—

and CAN'T—Be Seen

on the AD Iceberg

# A Planning Guide to Help You Work With Your **AD Care Team** to Optimize Treatment

The information contained in this publication is intended to reinforce and supplement information you receive from your healthcare team. It is not a substitute for medical advice from your physician. If you have questions about the information you read in this publication, please discuss them with your healthcare provider.

This has been produced as a patient education resource by Pfizer Inc.

**MEDICAL AFFAIRS** 

# How to Use This Planning Guide

### The Iceberg



Consider the popular phrase, *the tip of the iceberg*. This means that only part of an iceberg is visible above the surface of the water, yet below the surface lies a much larger piece of the iceberg that cannot be seen. It's a commonly used image to help explain situations where what you see doesn't tell the full story.<sup>1</sup>

The iceberg is a useful metaphor to explain what's happening in your body when you're living with atopic dermatitis (AD), a chronic or recurring form of eczema.<sup>2</sup> **That's because the signs and symptoms of AD**—

dry skin, red skin, itching, and patches that may appear on various parts of the body are just the tip of the iceberg.<sup>1,2</sup> AD is an immune system disease marked by chronic inflammation.<sup>3</sup> This means that inflammation may still be occurring below the surface of your skin even when there may be no visible signs of the disease.<sup>3</sup>

### This publication will help you:



**Define AD, also known as eczema,** as well as describe the common signs and symptoms of AD



### Understand the potential causes

of AD—the physical and other factors associated with the disease, the environmental triggers that may make it worse, and the reasons for skin barrier dysfunction

**Explain the other medical conditions** that may occur with AD

	Ider
4	for /
· ·	of A

### dentify available treatment options

**for AD** while understanding the core goals of AD treatment—namely, *reducing itching and skin irritation and keeping skin well hydrated and protected*, while preventing flares and infections<sup>4</sup>

### Describe how AD can affect your

**quality of life** (including the associated emotional challenges that may impact patients and their caregivers) and the importance of regularly communicating with your healthcare team about important treatment-related issues

### Support for Treatment Decision-Making

This is a different type of patient resource in that it's intended to support treatment decision-making between patients and caregivers and their healthcare professionals. The medical content is more in-depth than traditional patient education materials. That is by design. Each section explains important clinical concepts and raises key issues you will want to discuss with your healthcare team during your treatment.

If you're a caregiver, the information in this publication may help you support a patient in need. If you're a patient, these new insights about AD may help you support your own treatment through improved communication and shared decision-making with your doctor.

This guide includes medical terms you may have never seen before. **Bolded** terms throughout each section are defined in the glossary.

### Treatment Takeaway

Gaining new insights about AD may help empower you to support your own treatment. Empowerment means gaining control over medical well-being and acting on the medical issues that a patient or caregiver defines as important.<sup>5</sup> Being empowered also involves partnering with your AD Care Team—your primary care physician, dermatologist, pediatrician, allergist, nurse practitioner, physician assistant, pharmacist, etc, to design a treatment plan that's right for you or for a person under your care.




### A Tip From the AD Iceberg

Patients should seek out as much information as possible about AD including clinical insights found in this brochure that may not be found in patient education materials—to support their treatment through enhanced patient-healthcare professional communication and shared decision-making.

# **Need-to-Know Information About AD**



### AD: A Chronic Inflammatory Disease Marked by a Range of Symptoms



Understand these key facts about AD. Then, in each section, mark down your personal questions and concerns when discussing your medical condition and treatment plan with your healthcare professionals.

### AD: a chronic inflammatory disease marked by a range of symptoms

AD is a chronic, relapsing, inflammatory disease.<sup>6</sup> Relapse means that the signs and symptoms of AD may return after a period of improvement.<sup>7</sup> Inflammation may still be occurring under your skin even when there may not be visible signs on your body.<sup>3,8,9</sup>



### A Tip From the AD Iceberg

Because underlying inflammation is always present in your body when you have AD—that is, it is occurring below the surface of the AD Iceberg—it's important to always adhere to your treatment plan as directed by your healthcare professional, even if your skin is clear and there are no visible signs of AD, unless your doctor instructs otherwise.<sup>3</sup>

### Medical Terms for Signs and Symptoms of AD

Multiple signs and symptoms characterize AD and the underlying inflammation that causes it. The following table shows how AD signs typically appear on the body (although an individual patient's signs may vary depending upon their skin tone):



<sup>a</sup>Reprinted from *The Lancet*, 387(10023), Weidinger S, Novak N. Atopic dermatitis. 1109-1122. Copyright 2016, with permission from Elsevier.

Principal Characteristics		
essive dry skin ( <b>xerosis</b> ) <sup>6</sup>		
<b>thema</b> : reddening of the skin <sup>9</sup>		
normal conditions on the skin, such as nps, sores, discoloration, or oozing and sting <sup>11</sup>		
ck, leathery skin patches ( <b>lichenification</b> ), urring as a result of scratching or rubbing <sup>6</sup>		
y skin, which is a main symptom and a for in the AD disease burden <sup>6</sup>		


AD usually first appears in childhood.<sup>4</sup> In fact, approximately 85% of patients with AD experience their first symptoms before the age of 5. But it's important to note how patterns of AD vary by age.<sup>10,12</sup> **Note:** the symptoms shown below are for illustrative purposes; your particular AD signs and symptoms may appear elsewhere on your body.



### Where do your AD signs appear?


On the diagram below, work with your healthcare professional to mark down exactly where your lesions are, then discuss with him or her how these areas may be treated.

### Age-related locations of AD<sup>10</sup>




Reprinted from The Lancet, 387(10023), Weidinger S, Novak N. Atopic dermatitis. 1109-1122. Copyright 2016, with permission from Elsevier.

- In infants, AD tends to appear mainly on the face, limbs, and trunk<sup>10</sup>
- In children (age 1-2 years and up), AD may appear on the skin on the inside of a joint that folds<sup>10</sup>
- In adolescents and adults, AD may appear on the wrists, ankles, and eyelids—as well as on the head, neck, and upper trunk; AD signs may also appear on the shoulders and scalp<sup>10</sup>



Treatment Takeaway

Itching—known by the medical term, **pruritus**—is a main symptom of AD and represents part of the disease burden experienced by patients and caregivers.<sup>6</sup> Pruritus may lead to what's known as the *itch-scratch cycle.* The term describes how the act of scratching damages the skin barrier (leading to itchier skin and prolonging the disease) and which may be caused by complex immune system mechanisms.<sup>13</sup>



### A Tip From the AD Iceberg

Your dermatologist, pediatrician, allergist, and other healthcare professionals may be ready to help you address the quality of life challenges associated with AD. You should share your concerns with your healthcare professionals. They can help you cope with disease-related obstacles that may be interfering with daily activities.

### Note your personal questions/issues to discuss with your healthcare team:

# 2


### The Causes of AD and the Environmental Factors That Can Worsen It

The iceberg metaphor helps explain what's happening above and below the surface of your skin when you have AD.


Look at the image below. It shows how healthy skin forms a natural barrier to external irritants. But it is believed that physical abnormalities in the outer layer of your skin (the **epidermis**)—along with **immune system** irregularities occurring below the surface of the skin—help explain the common signs of AD.<sup>14</sup>

In clinical terms, the activity under your skin causes damage to the epidermis.<sup>14</sup> The image shows how your immune system is triggered due to *skin barrier dysfunction*, which allows irritants, micro-organisms, and **allergens** to penetrate the skin and cause cellular interactions that lead to chronic inflammation.<sup>14,15</sup>

### Above and Below the Skin's Surface: An Image and an Iceberg<sup>1,14,15</sup>



AD is often associated with the patient's and their family members' medical histories.<sup>9</sup> But external factors may also contribute to the development of AD or be related to severity. Here are just a few of the things that can trigger AD or worsen it.





There may be times when triggers will cause your AD to worsen significantly. This is called a *flare*.<sup>21</sup> Flares may be caused by external or internal triggers—such as food allergies, stress, or hormones—which may increase inflammation in the body and lead to a bad rash.

Flares may require special treatments, such as those involving prescription medications.<sup>4</sup>


Note your personal questions/issues to discuss with your healthcare team:

Treatment Takeaway It's important to try to identify your personal triggers to avoid them and the disease activity they may provoke. Understanding your triggers is key to help manage your symptoms.<sup>22</sup> Be sure to document and share your AD experiences with your healthcare professional to help pinpoint your specific triggers.

### AD and Other Associated Medical Conditions— **Known as Comorbidities**

If you have AD, you may have other health problems known as **comorbidities**, which may be physical or psychological in nature.<sup>18,23</sup>

Asthma and allergies, in particular, are associated with AD.<sup>18,23</sup> Atopic march is a specific term that describes the natural progression of allergic diseases that sometimes occurs in patients with AD, often beginning early in life.<sup>6,24</sup> Statistics show how common the atopic march is.



### **Physical comorbidities: examples**

Other physical comorbidities linked to AD include **bacterial infections** and **viral infections**.<sup>26</sup> Problems with the epidermal skin barrier make patients with AD more likely to experience these and other types of infections.

Some patients may easily get staph infections.<sup>27</sup> Data show that more than 90% of patients with AD already have staph existing on their skin (although it may have not yet caused an infection). It's important to recall the challenges of the itch-scratch cycle previously discussed, which may worsen and prolong AD.<sup>13</sup>

Studies have shown how frequently comorbidities may occur among patients with AD. The following table presents consolidated data from multiple studies about the prevalence of 3 AD-related comorbidities asthma, hay fever, and food allergies—among children and adults<sup>28</sup>:

ercent of Patients Experiencing Common AD-Related Comorbidities in a 1-Year Period <sup>28</sup>		
	Children, %	Adults, %
Asthma	19.8	18.7
Hay fever	34.4	28.4
Food allergy	15.1	13.2

### **Psychological comorbidities: examples**

Comorbidities of an emotional nature, which tend to affect children with AD, include<sup>29</sup>:

- Depression
- Anxiety
- Behavior disorders

If you are experiencing any of these difficulties, please consult with your doctor.

Treatment Takeaway

Comorbidities among patients with AD are common.<sup>25</sup> But remember, every patient's situation is different. AD is linked to a complex mix of genetic and environmental factors.<sup>16,17,30,31</sup>

Work with your healthcare professional to better understand the specific factors that contribute to your condition.

Note your personal questions/issues to discuss with your healthcare team:






## The Goals of AD Medical Care and Available Treatment Options

Medical guidelines established for the treatment of AD emphasize the importance of reducing itching and repairing the skin barrier to avoid worsening your condition or that of your child.<sup>32</sup> Keeping skin well hydrated and protected is central to all AD treatment approaches.<sup>4</sup>

There are several steps you can take each day to help keep your skin hydrated and protected.<sup>4</sup> They include<sup>33</sup>:





In addition to the above steps, your healthcare professional may recommend nonpharmacologic topical treatments—which include creams, lotions, and ointments—to apply externally to the skin.<sup>34</sup>


Another type of nonpharmacologic treatment is wet wrap therapy.<sup>4,35,36</sup> Here a moisturized layer of cotton and bandages is applied over topical treatments to help increase skin hydration and decrease itching.

Sometimes, prescription medications may be needed to help treat your AD. They include:

- Topical corticosteroids (TCS)<sup>6</sup>
- Topical calcineurin inhibitors (TCI)<sup>6</sup>
- Topical phosphodiesterase-4 inhibitor (PDE-4i)<sup>37</sup>
- Systemic treatments (pills or injectable drugs that work inside the body)<sup>7</sup>

Note your personal questions/issues to discuss with your healthcare team:





For caregivers, helping patients may lead to physical and emotional exhaustion due to the many hours of nighttime care required by pediatric sufferers—not to mention feelings of hopelessness, guilt, or sadness over their loved ones' medical issues.<sup>38,40</sup> Quality of life problems may be linked to a patient's disease severity: that is, lifestyle challenges may be more burdensome when a patient experiences significant skin discomfort and sleep disturbance.<sup>38,42</sup>



A tool is available to help you track your AD and generate information for your medical team. It is the Patient Oriented Eczema (POEM) Scale. This questionnaire lets you document your signs and symptomsinformation that you can share with your healthcare professionals to help them monitor and evaluate your AD.43

### Treatment Takeaway

It is important to regularly discuss quality of life challenges with your healthcare professional team to help them evaluate the effectiveness of your treatment plan (and to make any required changes) as well as to determine other types of medical/healthcare support you may need to manage your AD.

AD can be a difficult condition to live with.<sup>38</sup> It's challenging to patients because of its symptoms and the changes it causes in physical appearance.<sup>39</sup> It may also cause burdens for caregivers who strive to help young patients in need.<sup>38</sup> In short, AD may directly affect quality of life.

For some patients, living with AD may hinder their social, academic, or professional activities depending on the severity of their condition. We have seen how AD tends to appear early in childhood. Patients often experience emotional distress due to embarrassment, social isolation, and feelings of helplessness and depression.38,40,41

## Resources for People With AD



The following organizations provide educational resources on atopic dermatitis and other skin disorders:

National Eczema Association (NEA)

www.nationaleczema.org

International Alliance of Dermatology Patient Organizations (IADPO) www.globalskin.org

Society for Pediatric Dermatology (SPD) www.pedsderm.net

American Academy of Dermatology (AAD) www.aad.org

# **Glossary of Key Terms**

Allergen	A substance that can a ragweed pollen, anima
Allergic rhinitis	Medical term for hay f Symptoms include nas eye itching, and postn
Bacterial infection	Of or pertaining to an
Comorbidities	The coexistence of 2 or given time. <sup>7</sup>
Cytokine	A small protein released between cells, on comr
Epidermis	The upper or outer lay
Erythema	Redness of the skin th occur with inflammati
Immune system	A complex bodily syste foreign substances. <sup>7</sup>
Lichenification	A condition marked by from excessive scratch
Pruritus	Clinical term for itchin
Systemic treatment	Any type of medicinal traveling through the
T cell	A white blood cell type system's ability to seel
Viral infection	An infection caused by
Xerosis	A condition marked by

cause an allergic reaction. Common allergens include nal dander, and mold.<sup>7</sup>

<sup>7</sup> fever, an allergic reaction that mimics a chronic cold. asal congestion, a clear runny nose, sneezing, nose and nasal drip.<sup>7</sup>

n infection caused by bacteria.<sup>7</sup>

or more disease processes experienced by a person at a

ed by cells that has a specific effect on the interactions nmunications between cells, or on the behavior of cells.<sup>7</sup>

ayer of the 2 main layers of cells that make up the skin.<sup>7</sup>

hat results from capillary congestion and which can tion.<sup>7</sup>

tem that helps provide protection against infections and

by the appearance of thick or leathery skin that results ching or rubbing.<sup>7</sup>

ng. Pruritus can result from a variety of conditions.<sup>7</sup>

al treatment that reaches cells throughout the body by e bloodstream.<sup>7</sup>

be that serves an important function in the immune ek out and destroy pathogens.<sup>7</sup>

by the presence of a virus in the body.<sup>7</sup>

by abnormal dryness of the skin.<sup>7</sup>



# Preparing for Your Next Appointment With Your Healthcare Professional

Your next appointment:


Healthcare professional:

Date:

Location:



List any other questions, issues, or concerns you would like to discuss with your healthcare professional (dermatologist, family practitioner, pediatrician, allergist, nurse practitioner, physician assistant, or pharmacist) during your next visit:



### A Tip From the AD Iceberg

The symptoms of atopic dermatitis are diverse.<sup>6</sup> That's why different healthcare professionals—an "AD Care Team" comprised of dermatologists, allergists, pediatricians, and other healthcare professionals—may be needed to provide specialized medical care.

### **Common AD Signs and Symptoms**

Itch

Redness

Dry, scaly skin

**Skin thickening** 

Lesions

### Structural Manifestations of Underlying Inflammation

Activated immune and epidermal cellular activity

Skin barrier abnormalities

**T-cell activation** 

### Release of inflammatory cytokines

References: 1. Goodman M. The Iceberg Model. http://www.ascd.org/ASCD/pdf/journals/ed\_lead/el200910\_kohm\_iceberg.pdf. 2002. Accessed April 20, 2020. 2. National Eczema Association. An overview of the different types of eczema. https://nationaleczema.org/eczema/types-of-eczema. Accessed April 20, 2020. 3. Jakasa I, Verberk MM, Esposito M, Bos JD, Kezic S. Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. *J Invest Dermatol.* 2007;127(1):129-134. 4. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy. 2006;61(8):969-987. 5. WHO Guidelines on Hand Hygiene in Health Care First Global Patient Safety Challenge Clean Care is Safer Care. http://apps.who.int/iris/bitstream/handle/10665/44102/9789241597906\_eng. pdf;jsessionid=5A9DA78A0E4ÉDED8E0E4DF474BBA4234?sequence=1. Accessed April 20, 2020. 6. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351. **7**. Medicinenet.com website. https://www.medicinenet.com/medterms-medical-dictionary/article.htm. Accessed April 20, 2020. **8**. National Eczema Association. Defending against disease with an anti-inflammation lifestyle. https://nationaleczema.org/defending-disease-anti-inflammation-lifestyle. Accessed April 20, 2020. **9**. Bieber T. Atopic dermatitis. *Ann Dermatol*. 2010;22(2):125-137. **10**. Weidinger S, Novak N. Atopic dermatitis. *Lancet*. 2016;387(10023):1109-1122. 11. American Society for Dermatologic Surgery website. Skin lesions. https://www.asds.net/skin-experts/skin-conditions/skin-lesions. Accessed June 22, 2020. 12. Simpson EL, Irvine AD, Eichenfield LF, Friedlander SF. Update on epidemiology, diagnosis, and disease course of atopic dermatitis. Semin Cutan Med Surg. 2016;35(suppl 5):S84-S88. 13. Harrison IP, Spada F. Breaking the itch-scratch cycle: topical options for the management of chronic cutaneous itch in atopic dermatitis. *Serimi Cutan Med Surg.* 2016;53(3):PDF 3):564-586. **13.** Hatrison 1P, Spade T. Bledking the Itch-Scatch Cycle: topical options for the management of chronic cutaneous itch in atopic dermatitis. *Medicines* (*Basel*). 2019;6(3):76. doi:10.3390/medicines6030076. **14.** Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. *Immunol Rev.* 2011;242(1):233-246. **15.** Cheape AC, Murrell DF. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis. *Expert Rev Clin Immunol.* 2017;13(5):415-423. **16.** Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. *Allergy Asthma Immunol Res.* 2016;8(3):181-190. **17.** Eichenfield LF, Boguniewicz M, Simpson EL, et al. Translating atopic dermatitis management guidelines into practice for primary care providers. *Pediatrics.* 2015;136(3):554-565. **18.** Martin PE, Eckert JK, Koplin JJ, et al. Which infants with eczema are at risk of food allergy? Results from a population-based cohort. Clin Exp Allergy. 2015;45(1):255-264. 19. National Eczema Association. What is atopic dermatitis? https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis. Accessed April 20, 2020. 20. Kanda N, Hoashi T, Saeki H. The roles of sex hormones in the course of atopic dermatitis. Int J Mol Sci. 2019;20(19):4660. doi:10.3390/ijms20194660. 21. Arthritis Foundation Website. Understanding RA Flares. https://www.arthritis.org/living-with-arthritis/pain-management/ Bares/ra-flare-up-severity.php. Accessed April 20, 2020. 22. Asthma and Allergy Foundation of America. Atopic Eczema (Atopic Dermatitis). https://www.aafa.org/eczema. Accessed June 1, 2020.
Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131(1):67-73. 24. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105(2):99-106; quiz 107-109, 117. 25. Kapoor R, Menon C, Hoffstad O, Bilker W, Leclerc P, Margolis DJ. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008;58(1):68-73. 26. Ong PY, Leung DY. The infectious aspects of atopic dermatitis. Immunol Allergy Clin North Am. 2010;30(3):309-321. 27. National Eczema Association website. Conditions related to eczema. https://nationaleczema.org/eczema/related-conditions. Accessed April 20, 2020. 28. Silverberg JL. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144-151. 29. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):428-433. 30. Hidaka T, Ogawa E, Kobayashi EH, et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. Nat Immunol. 2017;18(1):64-73. 31. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131(2):295-299.e291-227. 32. Fleischer DM, Udkoff J, Borok J, et al. Atopic dermatitis: skin care and topical therapies. Semin Cutan Med Surg. 2017;36(3):104-110. 33. Ntuen E, Taylor SL, Kinney M, O'Neill JL, Krowchuk DP, Feldman SR. Physicians' perceptions of an eczema action plan for atopic dermatitis. J Dermatolog Treat. 2010;21(1):28-33. 34. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.e12. 35. Gittler JK, Wang JF, Orlow SJ. Bathing and associated treatments in atopic dermatitis. Am J Clin Dermatol. 2017;18(1):45-57. **36.** Tollefson MM, Bruckner AL; Section On Dermatology. Atopic dermatitis: skin-directed management. *Pediatrics*. 2014;134(6):e1735-e1744. **37.** Li H, Zuo JH, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. *Front Pharmacol*. 2018;9:1048. doi:10.3389/fphar.2018.01048. **38.** Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the national eczema association. *J Invest Dermatol*. 2017;137(1):26-30. **39.** Lifschitz C. The impact of atopic dermatitis on quality of life. *Ann Nutr Metab*. 2015;66(suppl 1):34-40. **40.** Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. *Int J Clin Pract*. 2006;60(8):984-992. **41.** Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949. 42. Vakharia PP, Chopra R, Sacotte R, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548-552.e3. 43. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519

